Dapagliflozin (SGLT2 inhibitor)

metabolic glycemic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

4 randomized trials (10,615 people, 12 weeks-2 years). All 4 improved their main endpoint.

Doses studied: 10 mg; 10 mg/day.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (11)

T8 Butt 2022 Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial doi:10.1161/CIRCULATIONAHA.122.061754
T8 Heerspink 2021 Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial doi:10.1093/eurheartj/ehab094
T6 Karalliedde 2022 Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial doi:10.3389/fcvm.2022.992327
T6 Russo 2025 Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients doi:10.34067/kid.0000001015
T5 Toulis 2017 All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in THIN database doi:10.1210/jc.2016-3446
T5 Onmez 2020 Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients doi:10.1080/13685538.2020.1758657
T3 Shihab 2024 Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice doi:10.25122/jml-2023-0343
T3 Mele 2026 Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction doi:10.1186/s12933-026-03133-z
TX Fioretto 2016 Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies doi:10.1007/s40266-016-0382-1
TX Marx 2021 Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial doi:10.1093/eurheartj/ehab092
TX Iyer 2023 Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality doi:10.7759/cureus.45525